{
    "root": "c82838dc-6934-4541-8a02-bd44ee5bb82a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "DAYVIGO",
    "value": "20250224",
    "ingredients": [
        {
            "name": "LEMBOREXANT",
            "code": "0K5743G68X",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11951"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (45000 WAMW)",
            "code": "8VAB711C5E",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE (11% HYDROXYPROPYL; 120000 MW)",
            "code": "NZ94SDL6WR"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "indications": {
        "text": "dayvigo indicated treatment adult patients insomnia , characterized difficulties sleep onset and/or sleep maintenance [ ( 14.1 ) ] .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended dose 5 mg taken per night , immediately going bed , least 7 hours remaining planned time awakening . may increased 10 mg based response tolerability . ( 2.1 ) maximum recommended dose 10 mg daily . ( 2.1 ) time sleep onset may delayed taken soon meal . ( 2.1 ) hepatic impairment : ( 2.3 ) \u25cb moderate hepatic impairment : initial maximum recommended 5 mg per night . \u25cb severe hepatic impairment : recommended .",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "dayvigo tablets available : 5 mg , pale yellow , round , biconvex , film-coated tablets , debossed `` 5 `` one side `` l\u0454m `` side . ndc 62856-405-30 , bottle 30 child-resistant closure ndc 62856-405-90 , bottle 90 child-resistant closure 10 mg , orange , round , biconvex , film-coated tablets , debossed `` 10 `` one side `` l\u0454m `` side . ndc 62856-410-30 , bottle 30 child-resistant closure ndc 62856-410-90 , bottle 90 child-resistant closure",
    "adverseReactions": "dayvigo contraindicated patients narcolepsy .",
    "indications_original": "DAYVIGO is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance [see Clinical Studies (\n                     \n                        14.1\n                     \n                     )].",
    "contraindications_original": "Recommended dose is 5 mg taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before the planned time of awakening. Dosage may be increased to 10 mg based on clinical response and tolerability. ( 2.1 ) The maximum recommended dose is 10 mg once daily. ( 2.1 ) Time to sleep onset may be delayed if taken with or soon after a meal. ( 2.1 ) Hepatic Impairment: ( 2.3 ) \u25cb Moderate hepatic impairment: Initial and maximum recommended dosage is 5 mg no more than once per night. \u25cb Severe hepatic impairment: Not recommended.",
    "warningsAndPrecautions_original": "DAYVIGO tablets are available as:\n                        \n                           5 mg, pale yellow, round, biconvex, film-coated tablets, and debossed with \"5\" on one side and \"L\u0404M\" on the other side. \n                        \n                        NDC 62856-405-30, bottle of 30 with child-resistant closure\n                        NDC 62856-405-90, bottle of 90 with child-resistant closure\n                        \n                           10 mg, orange, round, biconvex, film-coated tablets, and debossed with \"10\" on one side and \"L\u0404M\" on the other side.\n                        \n                        NDC 62856-410-30, bottle of 30 with child-resistant closure\n                        NDC 62856-410-90, bottle of 90 with child-resistant closure",
    "adverseReactions_original": "DAYVIGO is contraindicated in patients with narcolepsy.",
    "drug": [
        {
            "name": "DAYVIGO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11951"
        }
    ]
}